BackgroundCheck.run
Search For

David J Standring8 Burnley Rd, Norwood, MA 02062

Known as:
Dave M Standring

David Standring Phones & Addresses

8 Burnley Rd, Norwood, MA 02062    781-4409891   

20 Rosemary St, Norwood, MA 02062    781-4409891   

242 Sea Ave, West Yarmouth, MA 02673    508-7907094   

240 Sea Ave, West Yarmouth, MA 02673   

Worcester, MA   

255 Sycamore Dr, Holden, MA 01520    508-8296098   

Get Report
Control this profile

Mentions for David J Standring

David Standring resumes & CV records

Resumes

David Standring Photo 21

Senior Manufacturing Engineer

Location:
242 south Sea Ave, West Yarmouth, MA 02673
Industry:
Medical Devices
Work:
Siemens Healthcare
Senior Manufacturing Engineer Utc Fire & Security 2003 - 2008
Manufacturing Engineer Texas Instruments 1995 - 2000
Manufacturing Engineer Prestone Products Corporation 1995 - 1995
Manufacturing Engineer
Education:
Boston University 1991 - 1995
Bachelors, Mechanical Engineering St. John's High School
David Standring Photo 22

David Standring

David Standring Photo 23

David Standring

Publications & IP owners

Us Patents

Β-L-2′-Deoxynucleosides For The Treatment Of Resistant Hbv Strains And Combination Therapies

US Patent:
7186700, Mar 6, 2007
Filed:
Sep 15, 2003
Appl. No.:
10/662641
Inventors:
David Standring - Milton MA, US
Jean-Pierre Sommadossi - Cambridge MA, US
April L. Patty - Medford MA, US
Maria Seifer - Clinton MA, US
Assignee:
Idenix Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A01N 43/04
A61K 31/70
A61K 31/715
US Classification:
514 49, 42 43, 42 50, 42 51
Abstract:
It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

2′-Branched Nucleosides And Flaviviridae Mutation

US Patent:
7824851, Nov 2, 2010
Filed:
Nov 17, 2003
Appl. No.:
10/715729
Inventors:
Jean-Pierre Sommadossi - Boston MA, US
Paolo LaColla - Capoterra, IT
David Standring - Milton MA, US
Vadim Bichko - San Diego CA, US
Lin Qu - Webster TX, US
Assignee:
Idenix Pharmaceuticals, Inc. - Cambridge MA
Universita Degli Studi Di Cagliari - Cagliari
International Classification:
C12Q 1/70
C12Q 1/68
A01N 43/04
A61K 31/70
C07H 19/00
US Classification:
435 5, 435 6, 536 281, 536 282, 536 271, 514 49, 514 25, 514 50, 514 44
Abstract:
The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from seine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (Sequence ID No. 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

Β-L-2′-Deoxynucleosides For The Treatment Of Resistant Hbv Strains And Combination Therapies

US Patent:
7928086, Apr 19, 2011
Filed:
Jan 9, 2007
Appl. No.:
11/651353
Inventors:
David Standring - Milton MA, US
Jean-Pierre Sommadossi - Cambridge MA, US
April L. Patty - Medford MA, US
Maria Seifer - Clinton MA, US
Assignee:
Novartis AG - Basel
International Classification:
A01N 43/04
A61K 31/70
A61K 31/715
US Classification:
514 49, 514 42, 514 43, 514 50, 514 51
Abstract:
It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

Β-L-2′-Deoxynucleosides For The Treatment Of Resistant Hbv Strains And Combination Therapies

US Patent:
8158606, Apr 17, 2012
Filed:
Mar 21, 2011
Appl. No.:
13/052750
Inventors:
David Standring - Milton MA, US
Jean-Pierre Sommadossi - Cambridge MA, US
April Patty - Medford MA, US
Maria Seifer - Clinton MA, US
Assignee:
Novartis, AG - Basel
International Classification:
A01N 43/04
A61K 31/70
A61K 31/715
US Classification:
514 49, 514 42, 514 43, 514 50, 514 51
Abstract:
It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

2'-Branched Nucleosides And Flaviviridae Mutation

US Patent:
2011012, Jun 2, 2011
Filed:
Oct 28, 2010
Appl. No.:
12/914914
Inventors:
Jean-Pierre Sommadossi - Boston MA, US
Paolo LaColla - Capoterra, IT
David N. Standring - Milton MA, US
Vadim Bichko - San Diego CA, US
Lin Qu - Webster TX, US
International Classification:
C12Q 1/70
C40B 40/06
US Classification:
435 5, 506 16
Abstract:
The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXGXXXT, of domain B of the RNA polymerase region, or is associated with such a mutation; The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

2'-Branched Nucleosides And Flaviviridae Mutation

US Patent:
2016016, Jun 16, 2016
Filed:
Dec 16, 2015
Appl. No.:
14/972009
Inventors:
- Cambridge MA, US
- Monserrato, IT
David N. STANDRING - Milton MA, US
Vadim BICHKO - San Diego CA, US
Lin QU - Webster TX, US
International Classification:
A61K 31/7072
C12Q 1/70
C12Q 1/18
A61K 38/21
Abstract:
The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

2'-Branched Nucleosides And Flaviviridae Mutation

US Patent:
2014028, Sep 25, 2014
Filed:
Feb 18, 2014
Appl. No.:
14/183438
Inventors:
- Cambridge MA, US
Paolo LACOLLA - Capoterra, IT
David N. STANDRING - Milton MA, US
Vadim BICHKO - San Diego CA, US
Lin QU - Webster TX, US
Assignee:
Idenix Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q 1/70
C12Q 1/04
US Classification:
424 857
Abstract:
The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.

Possible Relatives

Lei Z Standring  Paul A Standring  David Last  David W Johnson  David Stamps  David L Stanard  David M Stanbery  David A Stanchfield  David J Stanciel  David Stancil 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.